RPTX
Income statement / Annual
Last year (2024), Repare Therapeutics Inc.'s total revenue was $53.48 M,
an increase of 4.58% from the previous year.
In 2024, Repare Therapeutics Inc.'s net income was -$84.69 M.
See Repare Therapeutics Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$53.48 M |
$51.13 M |
$131.83 M |
$7.60 M |
$135.00 K |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$13.38 M
|
$13.24 M
|
$116.72 M
|
$87.85 M
|
$38.78 M
|
$968.00 K
|
$407.00 K
|
$102.00 K
|
| Gross Profit |
$40.10 M
|
$37.89 M
|
$15.11 M
|
-$80.25 M
|
-$38.64 M
|
-$968.00 K
|
-$407.00 K
|
-$102.00 K
|
| Gross Profit Ratio |
0.75
|
0.74
|
0.11
|
-10.56
|
-286.22
|
0
|
0
|
0
|
| Research and Development Expenses |
$116.87 M
|
$133.59 M
|
$120.50 M
|
$91.17 M
|
$41.00 M
|
$19.89 M
|
$9.91 M
|
$4.40 M
|
| General & Administrative Expenses |
$29.68 M
|
$33.76 M
|
$32.56 M
|
$26.21 M
|
$14.35 M
|
$0.00
|
$2.91 M
|
$1.77 M
|
| Selling & Marketing Expenses |
$2.54 M
|
$0.00
|
$2.34 M
|
$2.19 M
|
$1.32 M
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$32.22 M
|
$33.76 M
|
$34.90 M
|
$28.41 M
|
$15.66 M
|
$4.95 M
|
$2.91 M
|
$1.77 M
|
| Other Expenses |
-$15.47 M
|
-$13.24 M
|
-$120.50 M
|
-$91.17 M
|
-$41.00 M
|
$0.00
|
-$1.14 M
|
-$1.47 M
|
| Operating Expenses |
$133.62 M
|
$154.12 M
|
$34.90 M
|
$28.41 M
|
$15.66 M
|
$24.84 M
|
$12.82 M
|
$6.18 M
|
| Cost And Expenses |
$147.00 M
|
$167.36 M
|
$151.63 M
|
$116.26 M
|
$54.44 M
|
$25.81 M
|
$12.82 M
|
$6.18 M
|
| Interest Income |
$10.39 M
|
$13.33 M
|
$5.63 M
|
$259.00 K
|
$240.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$1.92 M
|
$1.95 M
|
$1.98 M
|
$1.47 M
|
$897.00 K
|
$968.00 K
|
$407.00 K
|
$102.00 K
|
| EBITDA |
-$90.22 M |
-$114.27 M |
-$17.82 M |
-$107.19 M |
-$53.41 M |
-$25.49 M |
-$13.51 M |
-$7.53 M |
| EBITDA Ratio |
-1.69
|
-2.23
|
-0.14
|
-14.1
|
-395.59
|
0
|
0
|
0
|
| Operating Income Ratio |
-1.75
|
-2.27
|
-0.15
|
-14.3
|
-402.24
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$10.27 M
|
$13.05 M
|
$5.90 M
|
$74.00 K
|
-$440.00 K
|
-$644.00 K
|
-$1.43 M
|
-$1.62 M
|
| Income Before Tax |
-$83.25 M
|
-$103.18 M
|
-$13.90 M
|
-$108.59 M
|
-$54.74 M
|
-$26.46 M
|
-$14.25 M
|
-$7.80 M
|
| Income Before Tax Ratio |
-1.56
|
-2.02
|
-0.11
|
-14.29
|
-405.5
|
0
|
0
|
0
|
| Income Tax Expense |
$1.44 M
|
-$9.38 M
|
$15.15 M
|
-$1.68 M
|
-$1.33 M
|
$761.00 K
|
$35.00 K
|
$0.00
|
| Net Income |
-$84.69 M
|
-$93.80 M
|
-$29.05 M
|
-$106.91 M
|
-$53.42 M
|
-$27.22 M
|
-$14.28 M
|
-$7.80 M
|
| Net Income Ratio |
-1.58
|
-1.83
|
-0.22
|
-14.07
|
-395.68
|
0
|
0
|
0
|
| EPS |
-2 |
-2.23 |
-0.69 |
-2.83 |
-1.45 |
-0.74 |
-0.9 |
-0.49 |
| EPS Diluted |
-2 |
-2.23 |
-0.69 |
-2.83 |
-1.45 |
-0.74 |
-0.9 |
-0.49 |
| Weighted Average Shares Out |
$42.41 M
|
$42.09 M
|
$41.92 M
|
$37.82 M
|
$36.90 M
|
$36.67 M
|
$15.79 M
|
$15.79 M
|
| Weighted Average Shares Out Diluted |
$42.41 M
|
$42.09 M
|
$41.92 M
|
$37.82 M
|
$36.90 M
|
$36.67 M
|
$15.79 M
|
$15.79 M
|
| Link |
|
|
|
|
|
|
|
|
